Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?

Autor:	P, Tarantino, H J, Burstein, N U, Lin, I E, Krop, E P, Winer, S J, Schnitt, E P, Hamilton, S A, Hurvitz, H S, Rugo, G, Curigliano, S M, Tolaney
Rok vydání:	2022
Předmět:	Ki-67 Antigen Oncology Aminopyridines Cyclin-Dependent Kinase 4 Humans Benzimidazoles Breast Neoplasms Female Hematology
Zdroj:	Annals of Oncology. 33:234-238
ISSN:	0923-7534
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::729b79003b8702847496928fa1713e91 https://doi.org/10.1016/j.annonc.2021.12.004 Zobrazit plný text záznamu